{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:00Z","timestamp":1792012320338,"version":"4.4.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Relapse remains the most common cause of treatment failure for patients with acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave prognosis. Multiple studies have identified the presence of measurable residual disease (MRD) assessed by flow cytometry before alloSCT as a strong predictor of relapse, but it is not clear how these findings apply to patients who test positive in molecular MRD assays, which have far greater sensitivity. We analyzed pretransplant blood and bone marrow samples by reverse-transcription polymerase chain reaction in 107 patients with NPM1-mutant AML enrolled in the UK National Cancer Research Institute AML17 study. After a median follow-up of 4.9 years, patients with negative, low (&amp;lt;200 copies per 105ABL in the peripheral blood and &amp;lt;1000 copies in the bone marrow aspirate), and high levels of MRD had an estimated 2-year overall survival (2y-OS) of 83%, 63%, and 13%, respectively (P &amp;lt; .0001). Focusing on patients with low-level MRD before alloSCT, those with FLT3 internal tandem duplications(ITDs) had significantly poorer outcome (hazard ratio [HR], 6.14; P = .01). Combining these variables was highly prognostic, dividing patients into 2 groups with 2y-OS of 17% and 82% (HR, 13.2; P &amp;lt; .0001). T-depletion was associated with significantly reduced survival both in the entire cohort (2y-OS, 56% vs 96%; HR, 3.24; P = .0005) and in MRD-positive patients (2y-OS, 34% vs 100%; HR, 3.78; P = .003), but there was no significant effect of either conditioning regimen or donor source on outcome. Registered at ISRCTN (http:\/\/www.isrctn.com\/ISRCTN55675535).<\/jats:p>","DOI":"10.1182\/blood.2019002959","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T22:59:25Z","timestamp":1578956365000},"page":"680-688","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":168,"title":["Molecular MRD status and outcome after transplantation in NPM1-mutated AML"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"},{"name":"Cancer Genetics Service, Viapath, Guy\u2019s Hospital, London, United Kingdom;"},{"name":"Department of Haematology, Guy\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hills","sequence":"first","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie","family":"Freeman","sequence":"first","affiliation":[{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Potter","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"},{"name":"Cancer Genetics Service, Viapath, Guy\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Jovanovic","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Ivey","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju Shankar","family":"Kanda","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohursingh","family":"Runglall","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Foot","sequence":"first","affiliation":[{"name":"Cancer Genetics Service, Viapath, Guy\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Valganon","sequence":"first","affiliation":[{"name":"Cancer Genetics Service, Viapath, Guy\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Khwaja","sequence":"first","affiliation":[{"name":"Department of Haematology, University College, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Cavenagh","sequence":"first","affiliation":[{"name":"Bart\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"first","affiliation":[{"name":"Bart\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7628-8694","authenticated-orcid":false,"given":"Hans Beier","family":"Ommen","sequence":"first","affiliation":[{"name":"University Hospital, Aarhus, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik Malthe","family":"Overgaard","sequence":"first","affiliation":[{"name":"Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Dennis","sequence":"first","affiliation":[{"name":"Christie Hospital, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Knapper","sequence":"first","affiliation":[{"name":"Department of Haematology, Cardiff University, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpreet","family":"Kaur","sequence":"first","affiliation":[{"name":"Royal Hallamshire Hospital, Sheffield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Taussig","sequence":"first","affiliation":[{"name":"Royal Marsden Hospital, Sutton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mehta","sequence":"first","affiliation":[{"name":"Bristol Haematology and Oncology Centre, Bristol, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Raj","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Novitzky-Basso","sequence":"first","affiliation":[{"name":"Beatson Cancer Centre, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Nikolousis","sequence":"first","affiliation":[{"name":"Heartlands Hospital, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Danby","sequence":"first","affiliation":[{"name":"Churchill Hospital, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila","family":"Krishnamurthy","sequence":"first","affiliation":[{"name":"Addenbrooke's Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Hill","sequence":"first","affiliation":[{"name":"University Hospital, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Finnegan","sequence":"first","affiliation":[{"name":"Belfast City Hospital, Belfast, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Alimam","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"},{"name":"Department of Haematology, Guy\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Hurst","sequence":"first","affiliation":[{"name":"Royal Victoria Infirmary, Newcastle, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johnson","sequence":"first","affiliation":[{"name":"Western General Hospital, Edinburgh, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-6999","authenticated-orcid":false,"given":"Anjum","family":"Khan","sequence":"first","affiliation":[{"name":"St James\u2019 Hospital, Leeds, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahuman","family":"Salim","sequence":"first","affiliation":[{"name":"Clatterbridge Cancer Centre, Liverpool, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-6678","authenticated-orcid":false,"given":"Charles","family":"Craddock","sequence":"first","affiliation":[{"name":"Queen Elizabeth Hospital, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Spearing","sequence":"first","affiliation":[{"name":"Christchurch Hospital, Christchurch, New Zealand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Gilkes","sequence":"first","affiliation":[{"name":"Department of Haematology, Cardiff University, Cardiff, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Gale","sequence":"first","affiliation":[{"name":"Department of Haematology, University College, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Burnett","sequence":"first","affiliation":[{"name":"Blackwaterfoot, Isle of Arran, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy\u2019s Hospital, London, United Kingdom;"},{"name":"Nottingham University Hospital, Nottingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grimwade","sequence":"first","affiliation":[{"name":"Department of Medical and Molecular Genetics, King\u2019s College, London, United Kingdom;"},{"name":"Department of Haematology, Guy\u2019s Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2020022706595930500_B1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2011.40.5977","article-title":"Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission","volume":"31","author":"Burnett","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020022706595930500_B2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020022706595930500_B3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2020022706595930500_B4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2020022706595930500_B5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"issue":"19","key":"2020022706595930500_B6","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020022706595930500_B7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2020022706595930500_B8","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2404637","article-title":"Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations","volume":"21","author":"Chou","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2020022706595930500_B9","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020022706595930500_B10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2020022706595930500_B11","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"32","key":"2020022706595930500_B12","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"31","key":"2020022706595930500_B13","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020022706595930500_B14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cncr.30361","article-title":"Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia","volume":"123","author":"Ravandi","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"2020022706595930500_B15","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2016.120","article-title":"Effect of measurable (\u201cminimal\u201d) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia","volume":"30","author":"Othus","year":"2016","journal-title":"Leukemia"},{"issue":"13","key":"2020022706595930500_B16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2009-12-258178","article-title":"Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia","volume":"116","author":"Buccisano","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2020022706595930500_B17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"2020022706595930500_B18","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia","volume":"36","author":"Morita","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020022706595930500_B19","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"2020022706595930500_B20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/MOH.0000000000000482","article-title":"Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?","volume":"26","author":"Craddock","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2020022706595930500_B21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/asheducation-2016.1.356","article-title":"MRD in AML: does it already guide therapy decision-making?","volume":"2016","author":"Ossenkoppele","year":"2016","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"4","key":"2020022706595930500_B22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.beha.2017.09.010","article-title":"AML in 2017: Advances in clinical practice","volume":"30","author":"Rowe","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"2020022706595930500_B23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers10070215","article-title":"Role of minimal (measurable) residual disease assessment in older patients with acute myeloid leukemia","volume":"10","author":"Buccisano","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2020022706595930500_B24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2014.9","article-title":"Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML","volume":"49","author":"Anthias","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2020022706595930500_B25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020022706595930500_B26","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020022706595930500_B27","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020022706595930500_B28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2020022706595930500_B29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/ejh.12336","article-title":"Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation","volume":"93","author":"Bastos-Oreiro","year":"2014","journal-title":"Eur J Haematol"},{"issue":"5","key":"2020022706595930500_B30","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2016.159343","article-title":"Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis","volume":"102","author":"Buckley","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2020022706595930500_B31","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2020022706595930500_B32","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u201cminimal\u201d) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2020022706595930500_B33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/bmt.2014.326","article-title":"A multigene array for measurable residual disease detection in AML patients undergoing SCT","volume":"50","author":"Goswami","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"50","key":"2020022706595930500_B34","doi-asserted-by":"crossref","first-page":"87944","DOI":"10.18632\/oncotarget.21322","article-title":"High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients","volume":"8","author":"Jentzsch","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"2020022706595930500_B35","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.bbmt.2017.03.017","article-title":"Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation","volume":"23","author":"Getta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2020022706595930500_B36","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2020022706595930500_B37","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2020022706595930500_B38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-018-0203-8","article-title":"Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia","volume":"54","author":"Craddock","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2020022706595930500_B39","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"2020022706595930500_B40","first-page":"2204","article-title":"Cord-Blood Transplantation in Patients with Minimal Residual Disease","volume":"375","author":"Hourigan","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2020022706595930500_B41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"issue":"18","key":"2020022706595930500_B42","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa074306","article-title":"Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia","volume":"358","author":"Schlenk","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"2020022706595930500_B43","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2020022706595930500_B44","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","article-title":"Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients","volume":"97","author":"Bill","year":"2018","journal-title":"Ann Hematol"},{"issue":"7","key":"2020022706595930500_B45","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"issue":"9","key":"2020022706595930500_B46","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","article-title":"A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML","volume":"129","author":"Knapper","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2020022706595930500_B47","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"5","key":"2020022706595930500_B48","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2020022706595930500_B49","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbmt.2015.10.024","article-title":"Myeloablative, but not reduced-intensity, conditioning overcomes the negative effect of flow-cytometric evidence of leukemia in acute myeloid leukemia","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/9\/680\/1717488\/bloodbld2019002959.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/9\/680\/1717488\/bloodbld2019002959.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T07:00:46Z","timestamp":1582786846000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/9\/680\/430249\/Molecular-MRD-status-and-outcome-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002959","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}